糖尿病神經病變市場規模、佔有率、成長分析、按疾病類型、按藥物類別、按分銷管道、按地區 - 行業預測，2024-2031 年

2022年，糖尿病神經病變的全球市場規模為36億美元，從2023年的38.5億美元成長到2031年的65.6億美元，預測期（2024-2031）預計複合年成長率為6.9%。

糖尿病神經病變是一種損害與高血糖相關的神經的疾病，也是長期糖尿病患者面臨的重大挑戰。目前尚無治療方法，因此有效的管理和預防策略至關重要。這種複雜性強調了監管機構核准新治療劑和治療方法的必要性。鑑於糖尿病患者糖尿病神經病變的高盛行率，該領域的公司存在巨大的市場機會。隨著認知和診斷的提高，對滿足糖尿病患者需求的創新解決方案的需求預計將激增，為醫療保健市場的成長和發展提供良好的前景。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究

糖尿病神經病變市場規模：依疾病類型

• 市場概況
• 周邊神經神經病變
• 自主神經病變
• 近端神經病變
• 局部神經病變

糖尿病神經病變市場規模：依藥物類別

• 市場概況
• 辣椒素
• 鴉片類藥物
  • 氫可酮
  • 其他
• 非類固醇消炎劑(NSAID)
  • Ibuprofen
  • 萘普生
• 抗憂鬱症
  • 三環抗憂鬱藥物（Tcas）
  • 阿米替林
  • 丙咪嗪
  • 血清素和去甲腎上腺素再回收抑制劑(SNRIS)
  • Duloxetine
  • 選擇性血清素再回收抑制劑（SSRI）
  • 西酞普蘭
  • 帕羅西汀
  • 抗驚厥藥
  • Gabapentin
  • Pregabalin
  • 托吡酯
• 其他

糖尿病神經病變市場規模：按分銷管道

• 市場概況
• 醫院藥房
• 零售藥房

糖尿病神經病變市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Abbott Laboratories
• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Pharmaceuticals, Inc.
• Astellas Pharma US, Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• NeuroMetrix Inc.
• Helixmith Co., Ltd.
• Johnson & Johnson Services, Inc.
• Daiichi Sankyo Company, Limited
• Ionis Pharmaceuticals, Inc.
• Akcea Therapeutics, Inc.
• Alfasigma USA, Inc.
• ExeGi Pharma LLC

結論和建議

Global Diabetic Neuropathy Market size was valued at USD 3.6 billion in 2022 and is poised to grow from USD 3.85 billion in 2023 to USD 6.56 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2024-2031).

Diabetic neuropathy, a nerve-damaging condition linked to hyperglycemia, poses significant challenges for long-term diabetes sufferers, where symptoms often go unnoticed until considerable nerve damage occurs. As there is currently no cure, effective management and preventive strategies are crucial. This complexity emphasizes the need for regulatory agencies to approve new treatment products and therapeutic approaches. With the high prevalence of diabetic neuropathy among individuals with diabetes, there exists a substantial market opportunity for companies operating in this sector. As awareness and diagnosis improve, businesses can expect a surge in demand for innovative solutions tailored to address the needs of those affected by this condition, presenting lucrative prospects for growth and development in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Neuropathy Market Segmental Analysis

Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is primarily driven by the increasing prevalence of diabetes worldwide, leading to a higher demand for diabetic neuropathy treatment. As diabetes rates continue to rise, the market is expected to experience steady growth throughout the forecast period. Contributing factors include the rise in obesity, coronary heart disease, and various complications associated with diabetes, such as neuropathy. Additionally, urbanization plays a significant role in this trend, fostering sedentary lifestyles characterized by increased carbohydrate intake and reduced physical activity, which further exacerbates the incidence of diabetes and, consequently, the need for effective management of diabetic neuropathy.

Restraints in the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market faces several restraints that impede its growth potential. One significant challenge is the high cost of medications specifically designed for treating this condition, which may deter patients from pursuing pharmaceutical options. Additionally, the increasing popularity of alternative treatments, such as radiotherapy and physiotherapy, presents competition as these methods are often perceived as more comfortable and capable of delivering satisfactory results. Furthermore, stringent regulations, instances of product recalls, and delays in obtaining clearances from regulatory bodies like the Food and Drug Administration also contribute to the difficulties faced by the market in expanding its reach and efficacy.

Market Trends of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is witnessing a dynamic trend characterized by innovations in high-tech therapeutic solutions aimed at enhancing treatment efficacy. During the forecast period, companies are focusing on developing advanced products, including transdermal patches, mouthwashes, and powders, to address the complexities of diabetic neuropathy. The introduction of sophisticated medication delivery systems, such as needle-free injection devices, is emerging as a key strategy to mitigate challenges associated with traditional pharmaceutical methods. This surge in demand for novel drug delivery forms-spanning oral, transdermal, parenteral, and inhalation routes-is propelling market growth, reflecting an increasing consumer and healthcare provider interest in effective management of the condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2024-2031)

• Market Overview
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2024-2031)

• Market Overview
• Capsaicin
• Opioid
  • Morphine
  • Others
• Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • Ibuprofen
  • Naproxen
• Antidepressants
  • Tricyclic Antidepressants (Tcas)
  • Amitriptyline
  • Imipramine
  • Serotonin and Norepinephrine Reuptake Inhibitors (Snris)
  • Duloxetine
  • Selective Serotonin Reuptake Inhibitors (Ssris)
  • Citalopram
  • Paroxetine
  • Anticonvulsant Drugs
  • Gabapentin
  • Pregabalin
  • Topiramate
• Other

Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies

Global Diabetic Neuropathy Market Size & CAGR (2024-2031)

• North America (Disorder Type, Drug Class, Distribution Channel)
  • USA
  • Canada
• Europe (Disorder Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma US, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroMetrix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helixmith Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alfasigma USA, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ExeGi Pharma LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations